Member Info for Taff8

Massive

Here guys

Get in early read today's rns

Usa deal

Huge contract

Under the terms of the licence agreement, Diurnal will receive a non-refundable upfront payment of $5.0 million, of which $3.5 million is in cash and $1.5 million is through the issue to Diurnal of 379,474 new Eton shares, and will receive an additional $2.5 million cash milestone payment upon first commercial sale in the US following regulatory approval and grant of Orphan Drug Status (currently anticipated in Q4 2020). Diurnal will receive a tiered royalty on sales ranging from low double-digits to high teens and is also due tiered sales-based milestone payments of up to $45 million in aggregate subject to annual sales thresholds.

On 70k bopd

ASSET WORTH £££BILLIONS WAS PRODUCING 67K BOPD

It just a shake to get stock, will push towards 4p

Should easily see 4p

Interesting if we go alone we could be multi billion company very soon

I've been in few week @27p and Kew there was placing Coming at some point, just glad it higher than my entry price,im happy to hold for few months and multiple my investments, been aroud for years and trust me investing always beat trading, have done both but never made money over 12mths from trading, have done very well from investing.

Manufacture of SNG001 drug product and other supply chain considerations.

Looks like we're going alone on this, huge huge

Looks like there onto something

Don't be fooled placing always was going to come, more news imminent

Just sit and wait

To date, early data from this double-blind, placebo-controlled trial have demonstrated that the antiviral responses in the lung (assessed using sputum biomarkers) are similar to those observed in the asthma trial, where we saw clinical benefit in lung function.

Dr Richard Marsden, CEO of Synairgen told Thailand Medical News, "We have worked intensively with the relevant authorities and collaborators to enable SNG001 to be assessed in Covid-19 patients. SNG001 has been well tolerated in clinical trials in over 200 respiratory patients to date and has accelerated lung function recovery in two Phase II asthma trials in patients with a cold or flu infection. A successful outcome from this trial in Covid-19 patients would be a major breakthrough in the fight against this coronavirus pandemic."

Dr Stephen Holgate, Medical Research Council (MRC) Professor of Immunopharmacology, said, "The reduced innate immune response that exists in the lung of those at most risk of serious Covid-19 disease such as older people and those with pre-existing lung disease makes such patients ideal candidates to receive inhaled SNG001 to replace their interferon deficiency. This is especially so because SARS-CoV-2, along with MERS-CoV and SARS-CoV, is equipped to evade this first line of viral defence. In the absence of a suitable vaccine, increasing the host's own immunity to enhance protection and virus elimination would seem a logical therapeutic approach."

Dr Tom Wilkinson, Professor of Respiratory Medicine at the University of Southampton and Trial Chief Investigator, further added, "We are facing an unprecedented health challenge with Covid-19 which desperately requires the rapid development of new therapeutic strategies. There are a limited number of candidate new treatments available and so it is vital we can rapidly generate high quality evidence on the role of these in Covid-19 patients. The UK research delivery and regulatory teams have worked incredibly effectively to enable this world leading trial to achieve approvals so rapidly which has enabled our motivated and highly expert team of researchers to get this vital study running straight away."

For more details, please view: https://www.synairgen.com/ (please do not overwhelm them with calls or product enquiries. The drug is in experimental stages and not meant for sale to individuals or even medical entities or companies, only government to government deals involving trials will be entertained at this stage.)

For constant updates on Covid-19 Drug Research updates, please keep on logging on to Thailand Medical News


Please help support this site by donating via paypal options below:
Make a Donation
PayPal – The safer, easier way to pay online!
MOST READ

BREAKING! More Emerging Chinese Research Studies Shows That The SARS-Cov-2 Coronavirus Also Attacks The Kidneys, Pancreas and Liver
Source: Coronavirus Research
Mar 11, 2020 14 days ago

BREAKING! Coronavirus Research:

Don't be surprised to see 300/400% day with good news

Not a bean